Cancer Family
Lipomatous Neoplasm
CI-CAN-00000216Explore in graph →
Non-malignant55 active trials1 approved drugs9 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000216Explore in graph →
Clinical trials
155 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05905341 | Study of PF-07224826, as a Single Agent or in Combination With Endocrine Therapy in Participants With Breast Cancer and Other Advanced Solid Tumors. | withdrawn | Phase 1 | 0 | PfizerINDUSTRY | 0 | Nov 8, 2023 | clinicaltrials |
| NCT03880123 | Selinexor in Combination With Ixazomib for the Treatment of Advanced Sarcoma | withdrawn | Phase 1 | 0 | Matthew InghamOTHER | 1 | Nov 27, 2020 | clinicaltrials |
| NY-ESO-1 Specific T Cells After Cyclophosphamide in Treating Patients With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma |
| withdrawn |
| Phase 1 |
| 0 |
| Fred Hutchinson Cancer CenterOTHER |
| 1 |
| Feb 3, 2016 |
| clinicaltrials |
Data updated 22 days agoSource updated Nov 8, 2023source: clinicaltrials